Stratification and selection of therapies to improve survival in severe alcoholic hepatitis

Table 1 Inclusion and exclusion of major trials on corticosteroids in severe alcoholic hepatitis

Trial	Inclusion criteria	Exclusion criteria
STOPAH trial	Clinical diagnosis of alcoholic hepatitis with mDF > 32	Patients with creatinine > 5.7 mg% or on renal support. Patients with gastrointestinal bleed and creatinine up to 5.7 mg% were not excluded. Also, patients with resolved sepsis were not excluded
Louvet et al[13] 2009	Severe alcoholic hepatitis with mDF > 32 and onset of jaundice within 3 months. Patients with treated infections were included	Gastrointestinal bleed within 15 days, peptic ulcers, Hepatitis B and C, neoplasm
GpreAH study	Clinical or biopsy proven alcoholic hepatitis with mDF < 90	Patients with sepsis, creatinine > 1.5 and recent gastrointestinal bleed were excluded
STASH trial	Clinical diagnosis of alcoholic hepatitis	Acute kidney injury, recent gastrointestinal bleed and active infections were excluded

mDF: Maddrey’s discriminant function.